Nasopharyngeal Carcinoma
Conditions
Brief summary
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.
Interventions
DRUGDalpiciclib Isetionate Tablets, Camrelizumab
Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Had histopathologically confirmed nonkeratinizing recurrent/metastatic NPC. 2. ECOG performance status of 0 or 1. 3. Progression after previous treatment with platinum-based dual-drug chemotherapy. 4. Progression after previous treatment with PD-1 inhibitors. 5. Experieced at least 1 line systemic therapy. 6. Subjects enrolled must have measurable lesion(s) according to response evaluation criteria in solid (RECIST) v1.1. 7. Adequate organ function assessed by laboratory parameters during the screening period. 8. Life expectancy more than 12 weeks. 9. Able to understand and sign an informed consent form (ICF). 10. Able to swallow the pill.
Exclusion criteria
1. Recurrent lesions suitable for radical treatment (radiotherapy or surgery). 2. Previous treatment over 3 lines. 3. Prior use of CDK4/6 inhibitors. 4. Patients with other malignancies. 5. Patients with known or suspected autoimmune diseases including dementia and seizures. 6. Multiple factors affecting the absorption of oral medications (e.g., dysphagia, chronic diarrhea, and bowel obstruction). 7. An excessive dose of glucocorticoids given within 4 weeks before enrollment. 8. Complications requiring long-term use of immunosuppressive drugs or systemic or local use of immunosuppressive-dose corticosteroids. 9. Patients with active pulmonary tuberculosis (TB) receiving anti-TB treatment or who have received anti-TB treatment within 1 year prior to screening. 10. HIV positive; HBsAg positive and HBV DNA copy number positive (quantitative detection ≥ 1000 cps/ml); chronic hepatitis C with blood screening positive (HCV antibody positive). 11. Any anti-infective vaccines such as influenza vaccine, varicella vaccine, etc., within 4 weeks before enrollment. 12. Women of childbearing age with a positive pregnancy test and lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | 1 year | Objective response rate is the rate of patients achieving complete response or partial response for a certain period of time after intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median progression-free survival (PFS) | 1 year | Progression-free survival is defined as the time to the date of death of any cause or the first progress at any site, censored on the last date of tumor evaluation if no progress has happened. |
| Median overall survival (OS) | 3 years | Overall survival is defined as the time to the date of death of any cause, censored on the last date of known survival if no death has happened. |
| Duration of response (DoR) | 1 year | Defined as the time from first documentation of objective response to radiological disease progression |
| Disease control rate (DCR) | 1 year | Disease control rate is the rate of patients achieving complete response, partial response or stable disease |
| Incidence of adverse events | 1 year | NCI-CTCAE 5.0 standard is adopted. |
Countries
China
Contacts
Primary ContactMing-Yuan Chen, MD, PhD
Backup ContactRui You, PhD
Outcome results
None listed